Premium
Regulatory Action to Protect Access to Hydroxychloroquine for Approved Rheumatic Indications During COVID‐19 in New Zealand
Author(s) -
Duffy Eamon,
Arroll Nicola,
Beasley Richard,
Hills Thomas
Publication year - 2021
Publication title -
arthritis and rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.106
H-Index - 314
eISSN - 2326-5205
pISSN - 2326-5191
DOI - 10.1002/art.41643
Subject(s) - medicine , hydroxychloroquine , adverse effect , randomized controlled trial , medical prescription , clinical trial , intensive care medicine , covid-19 , pharmacology , disease , infectious disease (medical specialty)